Working… Menu

Omega-3 Supplementation and Attention-deficit-hyperactivity Disorder (ADHD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00874536
Recruitment Status : Completed
First Posted : April 2, 2009
Last Update Posted : July 30, 2013
Israel Association of Pediatricians
Information provided by (Responsible Party):
gal dubnov raz, Sheba Medical Center

Brief Summary:
It is assumed that only 1/5 of children diagnosed with attention-deficit-hyperactivity disorder (ADHD) are treated. New treatment modalities are urgently needed. Omega-3 fatty acids have been used in this setting, yet results are conflicting. The parent omega-3 fatty acid alpha-linolenic acid (ALA) has only been used in one trial. 40 children diagnosed with ADHD will be randomized to consume either ALA or placebo for two months. Baseline and end assessments will include ADHD-related questionnaires and a computerized test. The investigators hypothesize that ALA supplementation will prove beneficial for children with ADHD.

Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Dietary Supplement: omega-3 fatty acid alpha-linolenic acid (ALA) Dietary Supplement: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Omega-3 Fatty Acid Supplementation on Behavior of Children With ADHD
Study Start Date : April 2009
Actual Primary Completion Date : June 2011
Actual Study Completion Date : June 2011

Arm Intervention/treatment
Experimental: ALA
This group will receive the ALA supplement
Dietary Supplement: omega-3 fatty acid alpha-linolenic acid (ALA)
3 grams of ALA-containing plant oil

Placebo Comparator: Placebo
This group will receive the placebo supplement
Dietary Supplement: Placebo

Primary Outcome Measures :
  1. ADHD symptoms [ Time Frame: 8 weeks ]
    scores of DSM and Conners questionnaires

Secondary Outcome Measures :
  1. Computerized test performance [ Time Frame: 8 weeks ]
    performance in a computerized test of attention

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ADHD diagnosis
  • informed consent

Exclusion Criteria:

  • refusal of any testing
  • any comorbidities
  • any medication or supplement use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00874536

Layout table for location information
Hadassah Medical Organization
Jerusalem, Israel, 91120
Sponsors and Collaborators
Hadassah Medical Organization
Israel Association of Pediatricians

Layout table for additonal information
Responsible Party: gal dubnov raz, Senior physician, Sheba Medical Center Identifier: NCT00874536     History of Changes
Other Study ID Numbers: GDR3-HMO-CTIL
First Posted: April 2, 2009    Key Record Dates
Last Update Posted: July 30, 2013
Last Verified: July 2013
Keywords provided by gal dubnov raz, Sheba Medical Center:
Additional relevant MeSH terms:
Layout table for MeSH terms
Attention Deficit Disorder with Hyperactivity
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms